Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Passage Bio pushes proceeds to $248m
Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.
Cambricon clambers for public listing
Chinese Academy of Sciences and its VC subsidiary TCL Capital are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.
Passage Bio takes $216m IPO journey
University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.
Revolution hits public markets in $238m IPO
The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.
Beam Therapeutics brings IPO to $207m close
The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.
Beam Therapeutics shines in $180m IPO
Genomic medicine developer Beam will raise $180m in a upsized initial public offering three years after being spun out of Harvard University.
Passage Bio reaches IPO stage
University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.
Revolution to make waves with IPO
The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.

Other News

Revolution Medicines to rule with $100m IPO
Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.
Cabaletta captures $74.8m IPO
University of Pennsylvania spinout Cabaletta has gone public after raising $74.8m in an initial public offering on the Nasdaq Global Select Market.
Biontech binds itself to public markets
Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.
Aprea closes $97.8m IPO
The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.
Aprea collects $85m in IPO proceeds
Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
Frequency attracts $84m in IPO
Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg